AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02806492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50-100ug phenylephrine before CPB
Description: In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP \<60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
Study NCT02806492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50-100ug phenylephrine during CPB
Description: In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
Study NCT02806492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decreasing CPB flow
Description: With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
Study NCT02806492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decreasing CPB flow AND 50-100ug phenylephrine
Description: In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
Study NCT02806492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing CPB flow
Description: In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
Study NCT02751749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Study NCT02166970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metallic stent deployment in hilar obstruction
Description: Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
Study NCT02166970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metallic stent deployment in hilar obstruction
Description: Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
Study NCT01667926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
Study NCT01667926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03708237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.
Study NCT03708237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.
Study NCT03708237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Opaque gel capsules filled with methylcellulose 1500 filler
Study NCT00283283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
Study NCT01915901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo (bismuth subsalicylate)
Description: placebo twice a day (BID)
Study NCT01915901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate (DMF)
Description: dimethyl fumarate (DMF) twice a day (BID)
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Womac
Description: Answer WOMAC at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Womac
Description: Answer WOMAC at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lequesne
Description: Answer Lequesne at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lequesne
Description: Answer Lequesne at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numerical Rating Scales (NRS)
Description: Answer NRS at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Numerical Rating Scales (NRS)
Description: Answer NRS at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPAQ
Description: Answer IPAQ at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IPAQ
Description: Answer IPAQ at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STS30
Description: Perform the STS30 at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STS30
Description: Perform the STS30 at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TUG
Description: Perform the TUG at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TUG
Description: Perform the TUG at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six-minute Test
Description: Perform the six-minute test at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Six-minute Test
Description: Perform the six-minute test at baseline, 6, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two days of lectures
Description: Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Two days of lectures
Description: Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Session with the psychologists
Description: Participate in a extra session group with the psychology team about their experiences with the program
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sessions with the physical therapy team
Description: Participate in a extra session group with the physical therapists
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sessions with the physical educators team
Description: Participate in a extra session group with the physical educators
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional habits to be improved
Description: Attend 3 extra meetings about nutrition.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tampa Scale for Kinesiophobia (TSK)
Description: Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
Study NCT02917655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tampa Scale for Kinesiophobia (TSK)
Description: Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
Study NCT02142205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00002
Description: IV Infusion
Study NCT01575730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermic intraoperative Peritoneal Chemoperfusion
Description: Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
Study NCT01575730 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hyperthermic intraoperative Peritoneal Chemoperfusion
Description: Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
Study NCT01575730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermic intraoperative Peritoneal Chemoperfusion
Description: Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
Study NCT00479830 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Eight Focus Groups Consisting of 8-10 Members Each
Study NCT03836573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation iPad Decision Aid Tool
Description: Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
Study NCT03834389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case- based Learning
Description: critical thinking, self efficacy, focus group interview
Study NCT00966563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mangafodipir
Description: Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
Study NCT00966563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02887820 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thromboelastograph
Description: A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
Study NCT00513162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Starting Dose of 10 mg/kg By Mouth Daily
Study NCT00513162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 25 - 50 mg/m\^2 By Mouth Daily
Study NCT02992847 — intervention group
Intervention type: OTHER
Intervention: Unenhanced MRI
Study NCT04127903 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Length of Right Main Stem Bronchus
Description: The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
Study NCT02054676 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography preoperative evaluation.
Description: Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):~* Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;~* Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).~All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible.
Study NCT02054676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative edentulous jaw segment parameters evaluation.
Description: Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.~Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).~The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:~* implant drill slippage deeper than planned;~* implant threads coverage;~* etc.
Study NCT02054676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endosseous dental implant placement.
Description: Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.~Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.~Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.~Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).~Bone and soft tissue augmentation are made if necessary after dental implant placement.
Study NCT02054676 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dental implant position evaluation.
Description: Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.~Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).~Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined.
Study NCT02054676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications.
Description: Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days.
Study NCT02054676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late postoperative soft tissue evaluation.
Description: Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.~The time after surgery is case depending before provisional and final crown placement.~Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.~Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving.
Study NCT00634842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
Study NCT00634842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
Study NCT04943354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taking a person's venous blood
Description: Collection of 5 ml of the patient's venous blood, carried out according to standard rules.
Study NCT02407210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azilsartan
Study NCT02407210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Study NCT01947712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dark chocolate with crossover to milk chocolate
Description: 40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
Study NCT01947712 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: milk chocolate with crossover to dark chocolate
Description: 40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
Study NCT04646369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: screening as usual
Description: Participants in this group will receive usual care at their pediatric primary care practice following information, psychoeducation, and referral to a mental health treatment provider
Study NCT04646369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Wizard 2.0
Description: Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
Study NCT04646369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Wizard 2.0 + SOVA
Description: Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment. SOVA is a peer-support website that social workers and doctors moderate on a 24 hour a day basis.
Study NCT01276769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Description: Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.~1 cycle = 21days 2-6cycles
Study NCT01276769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and epirubicin
Description: Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.~1 cycle = 21days~2-6cycles
Study NCT03562390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.
Study NCT04351269 — intervention group
Intervention type: DEVICE
Intervention: CanGaroo Envelope
Description: CanGaroo Envelope with Cardiac Implantable Electronic Device (CIED) implantation
Study NCT04351269 — intervention group
Intervention type: DEVICE
Intervention: TYRX Envelope
Description: TYRX Envelope with Cardiac Implantable Electronic Device (CIED) implantation
Study NCT01603433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapheon™ Closure System
Description: Sapheon™ Closure System for the treatment of incompetent saphenous veins.
Study NCT02221999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02221999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02221999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02221999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02221999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist
Description: Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
Study NCT02221999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT03598699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXR-159
Description: AXR-159 Ophthalmic Solution
Study NCT03598699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: AXR-159 Ophthalmic Solution Vehicle